• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • CTX cells for Stroke Disability
    • CTX cells for Critical Limb Ischaemia
    • hRPCs for Retinal Disease
    • CTX-derived Exosomes
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Observational study in stroke
    • Phase I trial in critical limb ischaemia
    • Phase I/IIa clinical trial in retinitis pigmentosa
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • Webcasts and Presentations
    • Financial Calendar
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • CTX cells for Stroke Disability
    • CTX cells for Critical Limb Ischaemia
    • hRPCs for Retinal Disease
    • CTX-derived Exosomes
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Observational study in stroke
    • Phase I trial in critical limb ischaemia
    • Phase I/IIa clinical trial in retinitis pigmentosa
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • Webcasts and Presentations
    • Financial Calendar
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Pioneering stem cell therapeutics

We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

The 100 to 1 share consolidation has taken effect

Learn More About ReNeuron

Latest News

View all

ReNeuron wins grant for retinal cell therapy development

Appointment of US-based Chief Medical Officer

Product Development Update

Positive pre-clinical data in nerve injury

Phase II stroke data presented at AHA conference

Share Price

More details

74p 0.000p

at 25-04-2018 5:37:04

15 minute delayed share price from London Stock Exchange provided by Euroland.

Share Price

More details

74p 0.000p

at 25-04-2018 5:37:04

15 minute delayed share price from London Stock Exchange provided by Euroland.

Our Products & Technologies

Lab working look at petri dish Read more

Clinical Trials

hRPCs for Retinitis Pigmentosa Read more

Investor Centre

Investor Centre banner image Read more

Subscribe here for our Press Releases:

© ReNeuron Group plc 2018 All rights reserved

Website design by Carr Kamasa Design

  • Privacy
  • Disclaimer